Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed 15 September 2026 client-serving dealings under UK Takeover Code Rule 8.5. It purchased 1,044,392 ordinary shares at 280.75p-281.00p and sold 912,238 shares at 280.75p-281.25p, implying net purchases of 132,154 shares. The filing reported no derivative transactions or related indemnity, option, or voting arrangements.

Analysis

This disclosure is not directional insider buying and should not be read as an expression of Investec’s view on Advanced Medical Solutions or the transaction outcome. The near-flat gross purchase/sale activity and only modest net inventory change are consistent with ordinary client facilitation and market-making by an adviser/joint broker; the relevant signal is liquidity around the 281p dealing area, not conviction.

For INVP, there is no identifiable P&L implication without knowing the residual inventory, hedge economics, commission capture, or the underlying offer terms. Broker-adviser fee income from a single UK small-cap mandate is immaterial to group earnings, while the disclosure creates no basis to infer either a higher competing bid or enhanced closing probability.

Immediate trading risk is that event-driven desks misclassify the disclosure as informed flow, briefly supporting the target’s price around the reported execution range. Over the next 1-3 months, the only material catalyst is a formal transaction update—offer documentation, scheme timetable, regulatory clearance, shareholder support, or a revised consideration level. A widening discount of the target price to announced consideration, rather than this filing, would be the actionable indicator of completion risk.

Key Decisions for Investors

• No standalone trade in INVP: treat the filing as operational/client-serving flow, not a catalyst. Reassess only if subsequent disclosures show persistent unhedged proprietary exposure or management quantifies material advisory-fee economics.
• For any existing Advanced Medical Solutions merger-arbitrage position, use the reported 280.75-281.25p range solely as a liquidity reference; size exposure from the spread to stated consideration and expected closing date, not from broker dealing activity.
• Set alerts for formal offer-document publication, regulatory milestones, and any target-price discount widening beyond normal execution friction. Those events—not Rule 8.5 turnover—would justify initiating or resizing a merger-arbitrage position.